Evidence map›Paper›PMID 36286282›Full record

ArticleJournal of cardiovascular development and disease2022

The CCR2

María José Garcés-Hernández, Karen Pedraza-Escudero, Nayely Garibay-Nieto, Joselin Hernández-Ruiz, Jessica Lakshmi Prieto-Chávez, Lourdes Andrea Arriaga-Pizano, Eréndira Villanueva-Ortega, Galileo Escobedo, Aaron Noe Manjarrez-Reyna, Juan Carlos López-Alvarenga and 2 more

Open access · goldAbstract read
In one paragraph

Article in Journal of cardiovascular development and disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

María José Garcés-HernándezChildhood Obesity Clinic, Hospital General de México Dr. Eduardo Liceaga, Ciudad de México 06720, Mexico.ORCID 0000-0001-9832-9207
Karen Pedraza-EscuderoChildhood Obesity Clinic, Hospital General de México Dr. Eduardo Liceaga, Ciudad de México 06720, Mexico.
Nayely Garibay-NietoChildhood Obesity Clinic, Hospital General de México Dr. Eduardo Liceaga, Ciudad de México 06720, Mexico.
Joselin Hernández-RuizClinical Pharmacology Unit, Hospital General de México Dr. Eduardo Liceaga, Dr. Balmis 148, Doctores, Cuauhtémoc, Ciudad de México 06720, Mexico.ORCID 0000-0002-0571-2563
Jessica Lakshmi Prieto-ChávezFlow Cytometry Laboratory, Instrumental Center, Health Investigation Coordination, Hospital de Especialidades del Centro Médico Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de México 06720, Mexico.ORCID 0000-0002-0720-4271
Lourdes Andrea Arriaga-PizanoFlow Cytometry Laboratory, Instrumental Center, Health Investigation Coordination, Hospital de Especialidades del Centro Médico Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de México 06720, Mexico.ORCID 0000-0003-4433-2106
Eréndira Villanueva-OrtegaChildhood Obesity Clinic, Hospital General de México Dr. Eduardo Liceaga, Ciudad de México 06720, Mexico.
Galileo EscobedoLaboratory of Immunometabolism, Research Division, General Hospital of México "Dr. Eduardo Liceaga", Ciudad de México 06720, Mexico.ORCID 0000-0002-9224-7400
Aaron Noe Manjarrez-ReynaLaboratory of Immunometabolism, Research Division, General Hospital of México "Dr. Eduardo Liceaga", Ciudad de México 06720, Mexico.ORCID 0000-0002-5194-228X
Juan Carlos López-AlvarengaPopulation Health and Biostatistics, School of Medicine, University of Texas Rio Grande Valley, Edinburg, TX 78539, USA.ORCID 0000-0002-0966-8766
José Luis Pérez-HernándezGastroenterology and Hepatology Department, Hospital General de México "Dr. Eduardo Liceaga", Ciudad de México 06720, Mexico.
Gloria Queipo-GarcíaDepartment of Human Genetics, Hospital General de México "Dr. Eduardo Liceaga", Ciudad de México 06720, Mexico.
Hospital General de México · MXMexican Social Security Institute · MXThe University of Texas Rio Grande Valley · US

Funding

Consejo Nacional de Ciencia y Tecnología SALUD-2013-1-202499Sertull Foundation PS-17-SA-000510
6 · The paper itself

Abstract

The differential contribution of monocyte subsets expressing the C-C chemokine receptor 2 (CCR2) to subclinical atherosclerosis in girls and boys is unclear. In this pilot study, we compared classical, intermediate, and nonclassical monocyte subsets expressing CCR2 in 33 obese children of both sexes aged 8 to 16 divided by carotid intima-media thickness (IMT), considering values above the 75th percentile (p75) as abnormally high IMT. Obesity was defined as body mass index above the 95th percentile according to age and sex. Flow cytometry analyses revealed that boys but not girls with IMT ≥ p75 displayed increased CCR2+ cell percentage and CCR2 expression in the three monocyte subsets, compared to boys with IMT < p75. The CCR2+ cell percentage and CCR2 expression in the three monocyte subsets significantly correlated with increased IMT and insulin resistance in boys but not girls, where the CCR2+ nonclassical monocyte percentage had the strongest associations (r = 0.73 and r = 0.72, respectively). The role of CCR2+ monocyte subpopulations in identifying an abnormally high IMT shows a marked sexual dimorphism, where boys seem to be at higher subclinical atherosclerosis risk than girls.

Indexed as

CCR2childreninsulin resistanceintima-media thicknessnonclassical monocytesobesity

Identifiers

PMID36286282
PMCPMC9604509
OpenAlexW4297982820

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.